GSK and Ionis Report Successful Hepatitis B Treatment Trial
GSK and Ionis Pharmaceuticals achieved a 19% functional cure rate in chronic hepatitis B patients using bepirovirsen in a Phase 3 trial. This contrasts with a 0% cure rate from standard treatments.
GSK and Ionis Pharmaceuticals have reported promising results from their Phase 3 trial of bepirovirsen, an investigational antisense oligonucleotide for treating chronic hepatitis B. The trial, known as B-Well, revealed a statistically significant functional cure rate of 19% among adult participants receiving bepirovirsen, a notable improvement over the 0% cure rate observed with standard care. Announced on September 25, 2026, these findings mark a significant advancement in hepatitis B treatment, potentially offering new hope for patients affected by this chronic condition.
Enjoyed this story?
Show the newsroom a little love — one tap per reader.
Liam covers climate solutions and the people helping the planet heal.
Be part of the good
Stories like this start with people who care. Share it, or submit your own uplifting story to inspire millions today.
